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  Aging is the major risk factor for the development of cardiovascular 
diseases (CVD). Pathological changes to arteries lead to vascular dysfunction 
and contribute to CVD events. Endothelial dysfunction and large elastic artery 
stiffness are two major vascular changes that occur with age, and precede the 
manifestation of overt CVD. SIRT1, a member of the sirtuins, a family of 
enzymes associated with improved longevity and health span, have reduced 
activity and/or expression with age, which correlates with vascular dysfunction in 
humans. This suggests that declines in SIRT1 activity may contribute to age-
related vascular dysfunction, and activation of SIRT1 may improve vascular 
function in older adults.  The purpose of this dissertation was to assess the 
effects of chronic SIRT1 activation with the small molecule activator SRT1720 on 
vascular function and to determine the mechanisms by which SIRT1 elicits 
beneficial effects in old and young male mice.  
 Aortic SIRT1 protein expression and activity were reduced with age, and 
restored with SRT1720 treatment in old mice. Endothelium-dependent dilation 
(EDD), a measure of vascular endothelial function, was reduced in old vehicle-
treated mice compared with young control mice (p < 0.05), but was restored in 
old mice with SIRT1 activation (p < 0.05). Arterial stiffness, as indicated by pulse 
wave velocity, was higher in old versus young mice (p < 0.01), and was 
selectively reduced with SIRT1 activation in old mice. 
 iv 
 Aortic superoxide production was higher in old mice treated with vehicle 
compared with young control animals, but was reduced with SIRT1 activation in 
old mice (both p < 0.05). SRT1720 treatment in old mice also increased arterial 
antioxidant enzyme expression compared to old vehicle-treated animals. Levels 
of inflammatory cytokines were increased in old vehicle-treated versus young 
control mice, whereas SIRT1 activation partially normalized arterial inflammation 
in old animals. 
 In conclusion, SIRT1 activation ameliorated the age-related decline in 
vascular endothelial function and reduced large elastic artery stiffness, and this 
was associated by normalization of arterial oxidative stress and inflammation. 
These results indicate that SIRT1 activation may represent a novel therapy for 
reducing age-associated vascular dysfunction, thereby reducing the associated 
increase in CVD risk and mortality. 
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CHAPTER II 
 
Introduction 
 
 
 The risk for the development of cardiovascular diseases (CVD) increases 
with advancing age. It is now appreciated that pathological changes in vascular 
structure and function contribute to the increases in CVD with advancing age.  
The development of vascular endothelial dysfunction, as indicated by impaired 
endothelium-dependent dilation (EDD), and increased large elastic artery 
stiffness, as characterized by aortic pulse wave velocity (PWV), precede the 
manifestation of overt CVD. Both EDD and PWV are known to independently 
predict future CVD events, and therapies aimed at reducing these adverse 
arterial changes are important to reduce CVD events. 
 SIRT1 is a nicotinamide adenine dinucleotide-dependent deacetylase 
associated with increased longevity and improved health span in mammals. 
Vascular SIRT1 expression and/or activity are reduced with advancing age, and 
this may contribute to age-related vascular dysfunction. However, it is unknown if 
specific SIRT1 activation can ameliorate vascular endothelial dysfunction and 
reduce arterial stiffness with age. In Chapter IV, I tested the hypothesis that 
SIRT1 activation with the direct activator SRT1720 can increase EDD and reduce 
PWV in old mice, and this would be associated with changes in vasodilator 
enzyme expression and levels of structural proteins.  
 Age-related vascular endothelial dysfunction and arterial stiffness are also 
associated with increases in vascular oxidative stress and inflammation. 
Increased vascular superoxide production is known to impair EDD in older 
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humans and rodents, and SIRT1 activation has been found to provide protection 
against oxidative stress and induce antioxidant enzyme expression. Similarly, 
vascular aging is associated with increases in activation of the key inflammatory 
transcription factor NF-!B. SIRT1 is known to reduce NF-!B activation via direct 
deacetylation of the NF-!B subunit p65. Interventions designed to reduce these 
two key pathological changes with aging may reduce age-related increases in 
CVD risk. Thus, in Chapter V, I hypothesized that SIRT1 activation with SRT1720 
would reduce arterial oxidative stress and inflammation in old mice.  
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Specific Aims 
 
Specific Aim 1 (Chapter IV): To determine if SIRT1 activation with SRT1720 
ameliorates the age-related decline in EDD and increases in PWV in mice  
 
Specific Aim 2 (Chapter V): To determine if SIRT1 activation with SRT1720 
reduces arterial oxidative stress and inflammation in old mice 
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Chapter III 
 
Review of Literature 
 
 
Clinical Significance 
 
 Cardiovascular diseases (CVD) are the leading causes of death in 
industrialized nations (68). Aging is the major risk factor for the development of 
CVD (51). The number of adults developing CVD such as coronary heart 
disease, hypertension, and stroke increases with age, as does the amount of 
older adults that develop subclinical CVD such as silent coronary atherosclerosis 
(51).  
 It is now known adverse alterations in vascular function and structure 
contribute to the increases in CVD (56). With advancing age, two major vascular 
changes contributing to CVD are increases in large elastic artery stiffness and 
impaired vascular endothelial function (51, 64). Large elastic artery stiffness is 
known to increase with CVD risk factors such as hypertension, 
hypercholesterolemia, diabetes mellitus, and end-stage renal failure (58, 93). The 
development of endothelial dysfunction precedes the manifestation of 
atherosclerosis (91, 92). Dysfunction in either the peripheral or coronary 
circulation is known to independently predict future cardiovascular events (5). 
The development of interventions designed to reverse vascular dysfunction in 
aging populations represent important therapeutic targets to reduce CVD events 
(52).  
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Arterial Stiffness and Aging 
 Large elastic artery stiffness has been found to be a major independent 
risk factor for CVD (51). This is reflected as a decrease in arterial compliance or 
the ability of the artery to accommodate increases in intravascular pressure by 
changing the internal diameter (75, 85). Individuals with elevated arterial stiffness 
are at increased risk for developing CVD (64). Therefore, therapies aimed at 
reducing age-associated arterial stiffness are important to reduce CVD events in 
the aging population (64). 
 
Assessment of arterial stiffness in humans 
 In humans, pulse wave velocity (PWV) is a non-invasive, highly 
reproducible method for determining stiffness (53). This method involves 
measuring the distance and time it takes a waveform to travel between two 
arterial sites, such as from the carotid artery to the femoral artery (53). PWV is 
expressed as the change in distance over the change in time (53). Carotid-
femoral PWV is the gold standard for measurement of arterial stiffness as it is 
predictive of future cardiovascular events and is considered to be the most 
clinically relevant, as it is measured along the aortic track (53, 64). Reductions in 
PWV are found with both pharmacological and life-style interventions, and this 
may greatly reduce CVD risk in older adults (69, 76)  
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Assessment of arterial stiffness in animal preclinical models 
 Changes associated with arterial aging in humans have also been found 
to occur in many species, such as rodents (50). Stiffness of large elastic arteries 
develops in rodents, and the structural changes are similar to those found in 
humans (52). Methodology used to assess aortic stiffness in humans can be 
used to assess the same processes in rodent models (74). PWV is similarly 
increased with age in mice, and can be determined along the aortic track (74). An 
advantage of assessment of PWV as a measure of arterial stiffness in rodents is 
that it allows for the direct assessment of interventions as it can be measured 
repeatedly (43).  
 
Structural Changes Contributing to Arterial Stiffness with Aging 
 Structural changes within the arterial wall and increases in vascular 
smooth muscle tone are thought to mediate the augmentation in stiffness that 
occurs with advancing age (50, 51, 68). Known structural changes include 
elevations in advanced glycation endproducts, vascular smooth muscle 
hypertrophy and calcification, fragmentation and decreases in elastin density, 
and increases in the total amount and the cross-linking of collagen (51, 84). 
Elevations in vascular smooth muscle tone are hypothesized to occur as a result 
of augmented sympathetic nerve activity and local increases in the release of 
vasoconstrictors relative to vasodilators (51). 
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Vascular Endothelial Function and Aging 
 The vascular endothelium, a single layer of cells on the lumen side of 
vessel walls, was once thought to be a structural, passive barrier between blood 
vessels and circulating factors in the blood (1). However, it is now additionally 
recognized as a critical tissue that exerts autocrine and paracrine actions on 
vascular tone and homeostasis via the production of both dilating and contracting 
substances (5, 13, 91). The location on the inner lining of blood vessels allows 
the endothelium to sense changes in both hemodynamic and circulating chemical 
factors (91). Vascular endothelial function decreases with age (51), as most 
commonly characterized by a reduction in endothelium-dependent dilation (EDD) 
(23, 49, 54, 82).  
 
Measurement of EDD in Humans  
 Endothelial dysfunction is a systemic disorder affecting both the coronary 
and peripheral vascular beds (1, 5). In humans, two methods to determine EDD 
are flow-mediated endothelium-dependent dilation (FMD) and intra-brachial 
artery infusion of endothelium dilators with measurement of changes in forearm 
blood flow (FBF) (5). Further, to ensure changes in EDD are due to dysfunction 
of the endothelium and not the underlying smooth muscle, it is essential to 
assess endothelium-independent dilation (EID) (13). This involves use of an 
exogenous vasodilator, such as sublingual nitroglycerin or infusion of sodium 
nitroprusside, to induce maximal vasodilation of the smooth muscle and 
subsequent measurement of the diameter of the artery being studied (13).  
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Measurement of EDD in Preclinical Animal Models  
 In rodent models EDD can be determined ex vivo using a pressure 
myograph (54, 66, 67). Arteries, such as the carotid and femoral, are removed, 
placed in a bath with physiological saline solution and cannulated onto 
micropipettes (54, 66). Changes in vessel wall diameters to increases in 
intraluminal flow or in response to endothelial-dependent and -independent 
agonists are determined microscopically (54, 66, 67). Furthermore, “pharmaco-
dissection” of the vasodilator response can be assessed with the addition of 
inhibitors or activators to the vessel bath to further probe mechanisms of EDD 
(54).  
 
Mechanisms of Impaired EDD with Aging 
  The reduction in EDD with aging is primarily attributed to decreases in the 
bioavailability of dilator substances produced by the endothelium, most notably 
nitric oxide (NO) and cyclooxygenase (COX)-derived vasodilators, with a 
concurrent increase in the production of contracting substances (5, 22, 57, 83). 
 NO is the primary vasodilator released by endothelial cells (EC) and it is 
the main contributor to basal vascular smooth muscle tone (91). Endothelial NO 
synthase (eNOS) is a constitutive enzyme present in EC, and it is stimulated to 
produce NO by a variety of stimuli, including mechanical activation via increases 
in blood flow or shear stress, and in response to agonists such as acetylcholine, 
bradykinin, and substance P (3, 29).  
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 A reduction in the bioavailability of NO is one key mechanism in the 
development of vascular endothelial dysfunction (21, 83). Various risk factors for 
CVD such as hypertension, hypercholesterolemia, diabetes, and smoking are 
also known to affect the bioavailability of NO (14). Reductions in the NO 
component of EDD are found with aging in both rodent (42, 54, 66) and human 
models (83). This is typically demonstrated by smaller decreases in EDD with 
inhibition of eNOS in old versus young vessels (54, 66, 83). However, a reduction 
in the expression of eNOS has not been definitively determined to mediate the 
decrease in NO bioavailability with aging. Protein expression of eNOS has been 
found to increase (10, 79, 90), decrease (17, 94), and not change (26, 79, 94) 
with age. 
 The COX enzymes catalyze the first step in the production of vasoactive 
prostanoids from arachidonic acid, resulting in the production of prostaglandin G2 
(PGH2) by either COX-1 or COX-2 (12). PGH2 is converted by downstream 
prostanoid synthases to produce one of five different prostanoids, prostaglandins 
(PG) D, E, F, and I and thromboxane (TXA2), which can elicit either 
vasoconstriction or vasodilation. Endothelial cells express both COX isoforms. 
Endothelial COX-1 is generally associated with production of the pro-atherogenic 
vasoconstrictor TXA2 (9). In the vasculature, COX-2 production of the 
prostacyclin (PGI2) through PGI2 synthase is associated with an anti-atherogenic 
phenotype, as PGI2 is a powerful vasodilator (48). As such, PGI2 is generally 
considered the major vasodilatory prostanoid, and its effects are thought to 
counter-balance TXA2-mediated vasoconstriction (63). The association of 
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increased CVD events with COX-2 inhibitors designed to treat arthritis or other 
inflammatory disorders is generally attributed to a reduction in vasoprotective 
COX-2 prostanoids, such as PGI2, relative to TXA2 resulting in an imbalance that 
leads to vasoconstriction and CVD events (22).  
 With aging, impairments in EDD have also been associated with 
reductions in COX-2-mediated dilation (78, 95). COX-2 dilation has also been 
reported to act as a compensatory mechanism to preserve vasodilation when NO 
bioavailability is reduced, as it has been shown that endothelial COX-2 
production of vasodilators can preserve EDD despite loss of NO (2, 36, 81). 
Therefore, investigation of COX-2 changes with age and other pathological 
states are important for therapies aimed at modifying age-related vascular 
dysfunction (22). 
 Changes with age in vascular expression of both COX isoforms have been 
reported. COX-1 has been found to increase (46, 60), decrease (17, 80) or not 
change (8) with age. COX-2 expression has been shown to increase with age 
(46, 60, 65) or not change (8, 24). Additionally, upregulation of COX-2 expression 
by ECs has been speculated as a mechanism to oppose vascular injury (9). 
Consistent with this, COX-2 mediated production of PGI2 is atheroprotective in 
female mice and mediates antioxidant effects (31). In addition, vasoprotective 
laminar shear stress has been found to increase the expression of endothelial 
COX-2 and PGI2 synthase (70, 87). 
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Pathophysiological Mechanisms Contributing to Vascular Dysfunction with 
Age 
 Endothelial dysfunction involves “endothelial activation,” which represents 
a shift from a vasodilatory, antioxidant, and anti-inflammatory phenotype towards 
a constrictive, pro-inflammatory phenotype along with the promotion of 
thrombosis and proliferation of vascular smooth muscle cells (20, 21). Increases 
in oxidative stress and inflammation are two of the machromechanistic processes 
associated with vascular aging in both human and rodent models (52). Therapies 
designed to reduce these two pathological processes are important to reduce 
arterial aging and the age-associated increase in CVD risk. 
 
Vascular Oxidative Stress 
 Oxidative stress results from an increase in the production of ROS relative 
to the capacity of endogenous antioxidant defenses (86). Concentrations of ROS 
in tissues are determined by the rate of their production and their breakdown by 
various antioxidants (28). With aging, animal models show increased production 
of superoxide (17, 42, 54) in the vasculature. Antioxidant enzyme system 
activities and expressions may also be changed with age, although this is not as 
clear. Extracellular superoxide dismutase (SOD) activity (39) has been found to 
increase in rodents, while expression has been found to both increase in rodents 
(30) and not change in humans (25). Manganese SOD (MnSOD) and copper-
zinc SOD activities are elevated in older rodents (39), while expressions are 
reported to not change with age (30) in rodents and in humans (25). Total 
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vascular SOD activity is decreased in older rodents (4). Elevations in ROS 
associated with aging may be due to both increases in production of ROS and 
possible decreases in antioxidant defense. 
 In humans, brachial artery infusion of ascorbic acid improves EDD in 
elderly sedentary populations, with no overt clinical disease (32, 83). These 
studies also showed that ascorbic acid had no effect on EID and did not improve 
EDD in younger subjects. TEMPOL, a SOD mimetic, selectively improves EDD in 
isolated carotid arteries from older mice (30, 54, 77). Chronic administration of 
TEMPOL also reduces arterial stiffness, as assessed by PWV, in older mice, 
while having no effect in young animals (34). These results suggest increases in 
oxidative stress with advancing age may contribute to the decline in EDD and 
increased large elastic artery stiffness.  
 
Vascular Inflammation  
 Arterial aging is known to include a shift in the gene expression pattern of 
pro-inflammatory cytokines (18, 20), even in the absence of CVD risk factors. 
Older, healthy adults with impaired EDD demonstrate elevations in EC protein 
expression of tumor necrosis factor (TNF)-", monocyte chemoattractant protein-
1, and interleukin (IL)-6 (24). Analysis of aged rodent vessels reveals increases 
in TNF-" (16, 18, 19), IL-6 (18), IL-17 (18), and IL-1# (18). Treatment of aged 
rats with etanercept, which binds and inactivates TNF-", is found to improve 
EDD and decrease vascular superoxide production and TNF-" expression (16). 
Comparatively, administration of recombinant TNF-" to young rats induces 
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increases in vascular superoxide production, and reduces EDD (16). Additionally, 
elevations in vascular inflammation can contribute to increases in large elastic 
artery stiffness with aging (50). In vascular smooth muscle cells, increased 
expression of inflammatory cytokines may contribute to pathological processes 
such as vascular smooth muscle hypertrophy (50). Similarly, in old mice 
reductions in PWV are associated with decreases in expression of arterial 
inflammatory cytokines (34, 77). These studies clearly show that elevations in 
vascular inflammation with advancing age can impair EDD and increase arterial 
stiffness. 
 A possible mediator in the role of inflammation with advancing age is the 
redox-sensitive transcription factor nuclear factor-! B (NF-!B) (20). NF-!B 
activation is greatly increased by intracellular ROS (11), and acts as a 
transcription factor to induce the expression of various pro-inflammatory 
cytokines, adhesion molecules, chemokines, and additional ROS production (6, 
41). NF-!B activity can be regulated by post-translational modifications, such as 
phosphorylation and acetylation of the subunit p65 (20). 
 Elevations in NF-!B p65 protein expression are found in EC obtained from 
older humans (24, 25) and in the aorta of aged mice (55). Inhibition of NF-!B 
signaling improves EDD in middle-aged and older non-diabetic overweight and 
obese adults (72) and in old mice (55). These improvements in EDD by inhibition 
of NF-!B are also associated with reductions in oxidative stress (55, 72). These 
studies clearly show that in addition to elevations in oxidative stress, age-related 
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increases in inflammation and NF-!B activation can mediate the development of 
vascular endothelial dysfunction with age.  
 
Sirtuins 
 The silent information regulator (Sir) proteins are a conserved family of 
proteins known as sirtuins (38). The sirtuins are nicotinamide adenine 
dinucleotide (NAD)-dependent deacetylases or ADP-ribosyltransferases (44, 45). 
Deacetylation and ADP-ribosylation reactions both require NAD and produce 
nicotinamide as a product (37). NAD and its reduced form NADH are essential 
cofactors in many redox reactions. The requirement of NAD for Sir2 deacetylase 
activity is interpreted as a possible mechanism for sensing the oxidation state or 
energy levels of cells (38, 45). 
 
SIRT1 
 Seven mammalian homologues of Sir2 have been identified, SIRT1-7 
(61), and all show ubiquitous expression in human tissues (62). SIRT1 is the 
closest homologue to yeast Sir2 (73), and most research has thus far focused on 
this sirtuin (40). The high degree of conservation of sirtuin proteins across phyla 
suggests they mediate important roles in physiology (35). 
 
SIRT1 and Aging 
 SIRT1 activity and expression are modified with age in numerous 
mammalian tissues (38). Aging is reported to decrease SIRT1 activity in hearts, 
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but not adipose tissue of aged rats (33). Reductions in vascular SIRT1 protein 
and gene expression with aging have been found in rodents and humans (27, 
47). Further, SIRT1 mRNA expression in saphenous veins from human subjects 
undergoing coronary bypass surgery is inversely correlated with age (47).  
 
SIRT1 and Vascular Function  
 Changes in SIRT1 activity can also directly affect EDD. Inhibition of 
SIRT1, with a dominant negative SIRT1 mutant, in rat aortic rings impairs EDD 
by inhibiting bioavailable NO, whereas EID is not affected (59).  Additionally, 
transgenic endothelium-specific overexpressing SIRT1 mice crossed with     
ApoE -/- mice fed a high-fat diet to induce endothelium dysfunction, demonstrate 
EDD comparable to wild type mice (97). In human subjects, endothelial cell 
expression of SIRT1 correlates with vascular endothelial function (27). Incubation 
of femoral arteries from young and old mice with the SIRT1 inhibitor sirtinol 
removes age-associated differences in EDD, indicating a loss of SIRT1 activity is 
a mechanism contributing to the decline in vascular function (27). SIRT1 
activation with resveratrol in vascular smooth muscle cells reduces calcification, 
a marker of arterial stiffness in vitro (84). These studies indicate that SIRT1 
activation may be another method to improve age-related impairments in EDD 
and elevations in large elastic artery stiffness.  
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SIRT1 and Oxidative Stress  
 Overexpression of SIRT1 and stimulation of SIRT1 activity with resveratrol 
decreases ROS production and increases MnSOD expression in EC (88). 
Similarly, SIRT1 overexpression and activation via resveratrol attenuates ROS 
production in EC treated with cigarette smoke extract (15). SIRT1 activation also 
induces expression of MnSOD (71, 89) and catalase (71). Thus, SIRT1 activation 
mediates protection against elevations in oxidative stress. 
 
SIRT1 and Inflammation  
 SIRT1 can directly deacetylate NF-!B subunit p65 resulting in inhibition of 
NF-!B transcriptional activity (96). In EC, SIRT1 inhibition increases acetylation 
of NF-!B subunit p65, and this results in elevated levels of TNF-" (7). Similarly, 
SIRT1 overexpression and activation with resveratrol decreases expression of IL-
6, TNF-" and NF-!B activation in EC treated with cigarette-smoke extract (15). 
Therefore, activation of SIRT1 can ameliorate increases in inflammation.  
 
Conclusions 
 In conclusion, aging is associated with impairments in vascular endothelial 
function and increases in arterial stiffness, and this is associated with elevations 
in vascular oxidative stress and inflammation. Age-related reductions in arterial 
SIRT1 activity may contribute to impairments in EDD and increases in large 
elastic artery stiffness. Additionally, activation of SIRT1 can ameliorate oxidative 
stress and inflammation; however, it is undetermined whether this can occur in 
! "*!
the context of vascular aging. The effects of specific SIRT1 activation on 
amelioration of age-related vascular dysfunction are unknown, and are the focus 
of the present studies. 
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Abstract  
 Alterations in vascular structure and function contribute to age-related 
increases in cardiovascular diseases (CVD). Two major vascular changes 
contributing to the increase in CVD with advancing age are vascular endothelial 
dysfunction, as indicated by impairments in endothelium-dependent dilation 
(EDD) and increases in large elastic artery stiffness, as assessed by aortic pulse 
wave velocity (PWV). SIRT1 is a member of the sirtuins, a family of enzymes 
associated with increased longevity and improved health span, and reductions in 
SIRT1 expression and/or activity occur with advancing age. We hypothesized 
that SIRT1 activation with the specific activator SRT1720 would increase EDD 
and reduce PWV in old mice. Young (4-9 months) and old (29-32 months) male 
B6D2F1 mice were treated with SRT1720 (100 mg/kg BW) or vehicle for four 
weeks, and young control mice (4-9 months) were also studied. Aortic SIRT1 
expression was reduced 47% and activity was decreased 193% in old vehicle-
treated mice compared with young control mice (both p < 0.05), and both were 
restored with SRT1720 treatment in old mice. Old mice treated with vehicle 
demonstrated a decline in EDD compared with young control mice (83 ± 3% vs 
95 ± 1%, p < 0.01), and this was reversed in old mice treated with SRT1720 (95 
± 1%, p < 0.01). SIRT1 activation with SRT1720 increased EDD in old mice by 
enhancing cyclooxygenase (COX)-2 mediated dilation, and this was 
accompanied by increased arterial COX-2 protein expression. Initial PWV was 
increased in both groups of old mice compared with the two groups of young 
mice (p < 0.005), but four weeks of treatment with SRT1720 selectively reduced 
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PWV in old mice treated with SRT1720 (401 ± 35 vs 366 ± 23 cm/s, p < 0.01). 
Aortic expression of collagen I was increased in old vehicle-treated mice 
compared with young control mice (p < 0.05), and this was reversed with 
SRT1720 treatment in old mice. SIRT1 activation with SRT1720 ameliorates the 
age-related decline in vascular endothelial function and reduces arterial stiffness. 
This suggests specific activation of SIRT1 may be a therapeutic target for arterial 
aging in humans. 
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Introduction 
 
 Advancing age is the major risk factor for the development of 
cardiovascular diseases (CVD), and changes in vascular structure and function 
are now known to contribute to CVD events (22). Two important vascular 
changes that occur with advancing age are endothelial dysfunction and increases 
in large elastic artery stiffness (22, 32). Therapeutic targets to reduce CVD 
events in the aging population include those aimed at reversing age-related 
vascular dysfunction (23). 
 Vascular endothelial dysfunction is indicated by reductions in endothelium-
dependent dilation (EDD) (9, 21, 25, 41). The age-related impairment in EDD is 
commonly attributed to alterations in the production of vasodilatory compounds, 
such as nitric oxide (NO) from endothelial NO synthase (eNOS) or prostanoids 
derived from cyclooxygenase (COX)-1 or COX-2 (2, 8, 27, 42). Reduction in the 
expression of these vasoactive enzymes has not been definitively determined to 
mediate the decrease in EDD with aging, as vascular protein expression has 
been found to increase (4, 19, 29, 33, 38, 45), decrease (6, 39, 46), or not 
change (3, 10, 11, 38, 46).  
 Assessment of large elastic artery stiffness is commonly determined by 
aortic pulse wave velocity (PWV) (24, 34). Mechanisms mediating the age-
related increase in arterial stiffness include alterations in expression of structural 
proteins, such as collagen I or advanced glycation end products, or reductions in 
levels of elastin (22, 23). 
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 SIRT1 is a nicotinamide adenine dinucleotide -dependent deacetylase and 
a member of the sirtuin family of enzymes (17). The sirtuins, and SIRT1 in 
particular, have been associated with improved longevity and health span, and 
have reduced activity and/or expression with age in many tissues (17). 
Decreased protein and mRNA expression of vascular SIRT1 expression have 
been reported in humans and rodents (12, 20). Recently, SIRT1 protein 
expression in endothelial cells obtained from young and older human subjects 
was found to correlate with vascular endothelial function (12), implicating a loss 
of SIRT1 protein with age-related vascular dysfunction. Previous studies have 
found SIRT1 mediates beneficial vascular effects, however many of these reports 
have used non-specific SIRT1 activators such as resveratrol or utilized genetic 
manipulation (5, 28, 48). SRT1720 is a small-molecule activator of SIRT1, and 
exerts many beneficial effects against age-related diseases, including increased 
lifespan in mice fed a high-fat diet (30, 31). Given the need to develop potential 
therapies to reduce the age-related incidence of vascular dysfunction, it is 
important to determine the effects of specific SIRT1 activation on the vasculature.  
 In the present study, we hypothesized that four weeks of treatment with 
SRT1720 would reverse vascular endothelial dysfunction and normalize large 
elastic artery stiffness in old mice. We sought to determine whether 
improvements in endothelial function were mediated by changes in arterial 
vasoactive enzyme expression and if reductions in stiffness were associated with 
changes in aortic structural proteins. 
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Methods 
Animals  
 Young (4-9 months) and old (29-32 months) male B6D2F1 mice were 
obtained from the National Institute on Aging rodent colony, and were fed normal 
rodent chow ad libitum. All mice were housed in an animal care facility at the 
University of Colorado at Boulder on a 12:12 light:dark cycle. Old and young 
mice were treated with 100 mg/kg body weight SRT1720 (Sirtris, a 
GlaxoSmithKline Co.; Cambridge, MA) or vehicle (40%PEG-400/0.5% Tween-80/ 
59.5% deionized water) for four weeks via oral gavage (30). Young cage control 
mice were also monitored for four weeks. Body weight was monitored weekly 
and at sacrifice. All animal procedures conformed to the Guide to the Care and 
Use of Laboratory Animals (NIH publication n. 85–23, revised 1996) and were 
approved by the UCB Animal Care and Use Committee. 
 
Arterial Protein Expression 
 Western blot analyses were performed on cleaned mouse aortas to provide 
sufficient tissue for analysis as described previously (13, 25, 35). Fifteen 
micrograms of protein was loaded on 4–12% polyacrylamide gels, separated by 
electrophoresis, and transferred onto nitrocellulose membranes for Western blot 
analysis. Antibodies for Western blot analysis included SIRT1 (1:1000; Abcam 
Inc.), p53 (1:1000; Cell Signaling), Lysine379-acetyl-p53 (1:500; Cell Signaling), 
eNOS (1:1000, BD Transduction), COX-1 (1:100, Cayman Chemical), COX-2 
(1:100, Santa Cruz), and Collagen I (1:1000; Stressgen). To account for 
! $&!
differences in protein loading, expression is presented normalized to GAPDH 
(1:1000; 37 kDa; Cell Signaling) expression. SIRT1 activity was determined as 
the ratio of the known SIRT1 substrate Lysine379-acetyl-p53 to total p53. These 
data also are expressed as a ratio of the mean of the young control group within 
a given set of lysates. 
 
Carotid Artery Vasodilatory Responses 
 EDD and endothelium-independent dilation (EID) were determined ex vivo 
in isolated carotid arteries as previously described (13, 25, 35, 36). Briefly, mice 
were anesthetized using isoflurane and euthanized by exsanguination via cardiac 
puncture. The carotid arteries were carefully excised, cannulated onto glass 
micropipettes, and secured with nylon (11-0) suture in myograph chambers (DMT 
Inc.) containing buffered physiological saline solutions. The arteries were 
pressurized to 50 mmHg at 37 °C and were allowed to equilibrate for 1 h. After 
submaximal preconstriction with phenylephrine (2 µM), increases in luminal 
diameter in response to acetylcholine (ACh: 1 x 10-9 – 1 x 10-4 M) with and 
without co-administration of the NO synthase inhibitor L-NAME, (0.1 mM, 30 min 
incubation), were determined. EDD also was determined in the presence of the 
COX inhibitor, Indomethacin (Indo), (0.01 mM, 60 min incubation) (44) and the 
COX-2 specific inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfon- amide 
(NS-398) (10 µM, 30 min incubation) (44). EID was determined by vasodilation in 
response to sodium nitroprusside (SNP: 1 x 10-10  - 1 x 10-4 M). 
All dose–response data are presented on a percent basis. Preconstriction was 
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calculated as a percentage of maximal diameter according to the following 
formula: 
Preconstriction (% ) = (Dm - Db)/Dm x 100 
Because of differences in maximal carotid artery diameter between young and 
old animals, vasodilator responses were recorded as actual diameters expressed 
as a percentage of maximal response according to the following formula: 
Relaxation (% ) = (Ds – Db)/Dm – Db) x 100 
Where Dm is maximal inner diameter at 50 mmHg, Ds is the steady-state inner 
diameter recorded after the addition of drug, and Db is the steady-state inner 
diameter following preconstriction before the first addition of drug. 
NO-dependent dilation was determined from the maximal EDD in the absence or 
presence of L-NAME according to the following formula: 
NO-dependent dilation (%) = Maximum dilationACh - Maximal dilationACh+L-NAME 
 
In vivo aortic pulse wave velocity 
 Aortic PWV was measured as described previously (15, 36). Mice were 
anesthetized with 2% isoflurane and placed supine on a heating board with legs 
secured to ECG electrodes. Aortic velocity was measured with Doppler probes at 
the transverse aortic arch and abdominal aorta. Pre-ejection time, the time 
between the R-wave of the ECG to foot of the Doppler signal, was determined for 
each site. Aortic pulse wave velocity was calculated by dividing the distance 
between the transverse and abdominal probes by the difference in the thoracic 
and abdominal pre-ejection times. 
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Statistics 
 Results are presented as mean ± SEM. Statistical analysis was performed 
with SPSS 17.0 software (IBM, Somers, NY, USA). For the ex vivo vasodilatory 
dose response, group differences were determined by repeated measures 
ANOVA. A paired t-test was used to analyze stiffness Pre vs Post PWV. For 
maximal dilation, protein expression, animal characteristics, and cross-sectional 
PWV comparisons between groups were made using ANOVA. Significance was 
determined using P < 0.05. 
 
Results  
SRT1720 restores age-related reduction in aortic SIRT1 expression and 
activity 
 SIRT1 protein expression was reduced 47% in aorta of old vehicle-treated 
mice compared with young control mice (p < 0.05), and SRT1720 treatment for 
four weeks restored expression in old mice, but had no effect in young animals 
(Figure 1A). Consistent with this, the expression ratio of acetyl-p53 to total p53 
was elevated 193% in aorta of old vehicle-treated mice compared with young 
control mice (p < 0.05), indicating reduced aortic SIRT1 activity (Figure 1B). This 
age-related increase in the acetyl-p53 to total p53 ratio was reversed in 
SRT1720-treated old mice demonstrating increased aortic SIRT1 activity with 
SRT1720 treatment (Figure 1B).  
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Figure 1 
 
Figure 1. SIRT1 expression and activity. (A) Aortic protein expression of SIRT1 
and (B) ratio of acetylated-p53 to total p53 in young control (YC), old vehicle-
treated (OV), young SRT1720-treated (YS), and old SRT1720-treated (OS) mice. 
Data are expressed relative to GAPDH and normalized to YC mean value. 
Representative Western blot images below. Values are mean ± SEM. *, p < 0.05 
vs YC; †, p < 0.05 vs OV. 
 
SIRT1 activation with SRT1720 restores EDD in old mice 
 Endothelium-dependent dilation (EDD) was reduced in old mice treated 
with vehicle compared to young control mice indicating an age-related decline in 
endothelial function (83 ± 3% vs 95 ± 1%, p < 0.01) (Figure 2A). SRT1720 
administration completely restored EDD in old mice (95 ± 1%, p < 0.01) (Figure 
2A) to levels in young animals. EDD was not different with SRT1720 treatment in 
young animals compared with young control mice (97 ± 1%) (Figure 2A). 
Endothelium-independent dilation (EID) (Figure 2B) and sensitivity to ACh were 
similar between all groups. In young mice treated with vehicle, EDD was not 
different compared with young control animals (98 ± 1%) (Figure 2C). Similarly, 
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EID (Figure 2D) and sensitivity to ACh were similar in young vehicle-treated mice 
compared with young control animals. Since vehicle gavage treatment had no 
effect on vascular function in young animals, only young control mice were used 
for the remaining measurements.  
 
Figure 2 
 
 
Figure 2. Endothelium-dependent and endothelium-independent dilation. Dose-
responses to the (A) endothelium-dependent dilator acetylcholine (ACh) and (B) 
endothelium-independent dilator sodium nitroprusside (SNP) in young control 
(YC), young SRT1720-treated (YS), old vehicle-treated (OV) and old SRT1720-
treated (OS) mice. Dose-responses to (C) ACh and (SNP) in YC and young 
vehicle-treated (YV) mice. Values are mean ± SEM. *, p < 0.05 vs YC; †, p < 
0.05 vs OV.  
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SIRT1 activation does not increase NO-mediated dilation in old mice 
 Inhibition of nitric oxide synthases (NOS) with L-NAME dramatically 
reduced dilation to ACh in both groups of old mice (all p < 0.01) (Figure 3A). As 
was seen in the old mice, blockade of NOS with L-NAME significantly reduced 
dilation in both young groups (both p < 0.01) (Figure 3B). NO-mediated dilation, 
the difference in dilation to ACh with L-NAME blockade versus without, was not 
different in young animals treated with SRT1720 versus young control mice (area 
under the curve (AUC), 320 ± 49 vs 279 ± 33, p > 0.5) (Figure 2C), but tended to 
be lower in old mice treated with vehicle compared to young control mice (AUC, 
192 ± 34, p = 0.1) (Figure 3C). However, NO-mediated dilation was similar in old 
mice treated with SRT1720 compared with old vehicle-treated mice (AUC, 189 ± 
25, p > 0.5) (Figure 3C). These data suggest SIRT1 activation restores the age-
related decline in EDD in old mice, but did not increase NO-mediated dilation.  
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Figure 3 
 
 
 
 
Figure 3. Nitric oxide (NO)-mediated endothelium-dependent dilation (EDD). 
EDD to acetylcholine (ACh) in the absence or presence of NO synthase inhibitor 
N-G-nitro-L-arginine methyl ester (L-NAME) in (A) old vehicle-treated (OV) and 
old SRT1720-treated (OS) mice and (B) young control (YC) and young 
SRT1720-treated (YS) mice. (C) NO-dependent dilation (area under the curve 
(AUC) to ACh - (AUC) to ACh + L-NAME) in YC, OV, YS and OS mice. Values 
are mean ± SEM. *, p=0.1 vs YC. 
 
 
SIRT1 activation with SRT1720 increases COX-mediated dilation in old mice 
 As NO-dependent dilation did not mediate the restoration in EDD in old 
SRT1720-treated mice, dilation to ACh was repeated in the presence of both L-
NAME and the non-specific COX inhibitor Indo. In vehicle-treated old mice, EDD 
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with combined NOS and COX inhibition was similar to dilation with NOS inhibition 
(40 ± 8% vs 40 ± 9%, p > 0.05) (Figure 4A). However, in old mice treated with 
SRT1720, inhibition of both NOS and COX vasodilators further reduced EDD 
compared with NOS inhibition alone (36 ± 7% vs 58 ± 5%, p < 0.05) (Figure 4A), 
and resulted in similar dilation compared with old vehicle-treated mice. In both 
groups of young mice, EDD with combined NOS and COX inhibition was not 
different compared with dilation with NOS inhibition (p > 0.05) (Figure 4D). These 
data suggest that COX vasodilators mediate the increase in EDD in old mice 
treated with SRT1720. 
 
SIRT1 activation with SRT1720 increases COX-2 dilation in old mice 
 To confirm that COX vasodilators mediate the improvement in EDD in old 
mice treated with SRT1720, dilation to ACh with Indo was repeated without NOS 
inhibition. Inhibition of COX vasodilators did not change dilation to ACh in old 
vehicle-treated mice (p > 0.05) (Figure 4B). However, in old SRT1720-treated 
mice inhibition of COX significantly reduced EDD compared with dilation to ACh 
alone (p < 0.01) (Figure 4C), and was similar compared to old animals treated 
with vehicle. These results confirm the earlier observation indicating COX 
vasodilators mediate the increase in EDD in old SRT1720-treated mice. With 
COX inhibition, EDD was slightly reduced in young control mice (p < 0.05) 
(Figure 4E), but not in young mice treated with SRT1720 (p > 0.05) (Figure 4F), 
but dilation was similar between the young groups. 
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 To determine the specific COX isoform mediating the increase in EDD in 
old mice treated with SRT1720, dilation to ACh was repeated in the presence of 
the COX-2-specific inhibitor NS-398. With specific COX-2 inhibition, dilation was 
unchanged in old vehicle-treated mice (p > 0.05) (Figure 4B). In old mice treated 
with SRT1720, COX-2 inhibition reduced dilation to ACh (p < 0.01) (Figure 4C), 
and this resulted in similar dilation compared with old vehicle-treated mice. 
Specific COX-2 inhibition did not change dilation to ACh in both young control 
mice and young mice treated with SRT1720 (both p < 0.05). These data suggest 
that SRT1720 increases EDD in old mice via COX-2 vasodilators.  
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Figure 4 
  
 
  
 
 
Figure 4. Nitric oxide (NO)-, cyclooxygenase (COX)-, and COX-2-dependent 
modulation of endothelium-dependent dilation (EDD). (A) EDD to acetylcholine 
(ACh) in the absence or presence of endothelial NO synthase inhibitor N-G-nitro-
L-arginine methyl ester (L-NAME) and L-NAME plus the COX inhibitor 
Indomethacin (Indo) in old vehicle-treated (OV) and old SRT1720-treated (OS) 
mice. EDD to ACh in the absence or presence of Indo or the COX-2 specific 
inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfon- amide (NS-398) in (B) 
OV and (C) OS mice. (D) EDD to ACh in the absence or presence of L-NAME 
and L-NAME + Indo in young control (YC) and young SRT1720-treated (YS) 
mice. (B) EDD to ACh in the absence or presence of Indo or NS-398 in (B) YC 
and (C) YS mice. Values are mean ± SEM. *, p < 0.05 vs ACh. 
 
 
SIRT1 activation with SRT1720 increases COX-2 protein expression in old 
mice  
 Aortic protein expression of eNOS and COX-1 were unchanged with age 
or SRT1720 treatment (Figure 5A & 5B). However, COX-2 protein expression 
was reduced 50% in old mice treated with vehicle compared with young control 
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mice (p = 0.05) (Figure 5C). SRT1720 treatment normalized COX-2 expression in 
old mice, but had no effect in young mice (Figure 5C). This data suggest old mice 
have reduced aortic COX-2 protein expression, and this is restored with 
SRT1720 treatment. 
 
Figure 5 
 
Figure 5. Aortic expression of vasodilatory enzymes. (A) Aortic protein 
expression of endothelial nitric oxide synthase (eNOS), (B) cyclooxygenase 
(COX)-1, (C) COX-2 in young control (YC), old vehicle-treated (OV), young 
SRT1720-treated (YS), and old SRT1720-treated (OS) mice. Data are expressed 
relative to GAPDH and normalized to YC mean value. Representative Western 
blot images below. Values are mean ± SEM. *, p = 0.05 vs YC; †, p < 0.05 vs 
OV. 
 
SIRT1 activation with SRT1720 reduces PWV in old mice 
 Initial pulse wave velocity (PWV) was higher in both groups of old mice 
compared with the two groups of young mice (p < 0.005), but similar amongst 
mice of the same age (Figure 6). PWV after 4 weeks of treatment was selectively 
reduced in old mice treated with SRT1720 (401 ± 35 vs 366 ± 23 cm/s, p < 0.01), 
whereas it was unchanged in old mice treated with vehicle and in young mice (p 
> 0.05) (Figure 6). This resulted in normalization of PWV in SRT1720-treated old 
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mice to levels of young control animals (Figure 6). This indicates that four weeks 
treatment with SRT1720 ameliorates age-associated arterial stiffness, while 
having no effect in young mice. 
 
Figure 6 
 
Figure 6. Large elastic artery stiffness. Aortic pulse wave velocity before (Pre) 
and after (Post) 4 weeks treatment in young control (YC), old vehicle-treated 
(OV), young SRT1720-treated (YS), and old SRT1720-treated (OS) mice. Values 
are mean ± SEM. *, p < 0.05 vs YC; †, p < 0.05 vs OV; §, p<0.05 vs Pre. 
 
 
SIRT1 activation with SRT1720 reduces aortic Collagen I expression 
 Collagen I precursor expression was increased 64% in aorta of old 
vehicle-treated mice compared with young control mice (p < 0.05) (Figure 7). 
SRT1720 treatment reduced aortic Collagen I levels in old mice (p = 0.05), 
however expression increased in young mice compared with young control mice 
(p < 0.01) (Figure 7). These data suggest that Collagen I expression is increased 
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in aorta of old mice, and SIRT1 activation with SRT1720 normalizes aortic 
Collagen I expression to the level of young control mice. 
 
Figure 7 
 
Figure 7. Aortic expression of Collagen I. Collagen I protein expression in young 
control (YC), old vehicle-treated (OV), young SRT1720-treated (YS), and old 
SRT1720-treated (OS) mice. Data are expressed relative to GAPDH and 
normalized to YC mean value. Representative Western blot images below. 
Values are mean ± SEM. *, p < 0.05 vs YC. 
 
 
Animal Characteristics 
 Animal characteristics of the groups are shown in Table 1. Body mass and 
carotid artery lumen maximal diameter were greater in old compared with the 
young control mice (p < 0.05).  SRT1720 had no effect on these variables in 
treated animals. Carotid artery preconstriction to phenylephrine was higher in YV 
mice (p < 0.05), but did not differ among the other groups. 
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Table 1. 
 
YC, young control; OV, old vehicle-treated; YV, young vehicle-treated; YS, young 
SRT1720-treated; OS, old SRT1720-treated. 
Values are mean ± SEM. *, p < 0.05 vs YC. 
 
 
Discussion 
 To our knowledge this is the first study to show specific SIRT1 activation 
ameliorates age-related vascular dysfunction. There are several key novel 
findings from this study. Activation of SIRT1 with SRT1720 restores aortic SIRT1 
expression and activity in old mice and this was accompanied by increased 
vascular endothelial dysfunction. The improvement in vascular function with 
SRT1720 was mediated by increased production of COX-2 vasodilators and 
increased arterial COX-2 expression in old animals. SRT1720-mediated SIRT1 
activation reduced large elastic artery stiffness in old mice to the level of young 
animals, and this was associated with reduced arterial collagen I expression. 
 
Arterial SIRT1 Expression and Activity  
 Our data confirms previous studies by our laboratory and by others 
 
YC OV YV YS OS 
Body Mass (g) 33 ± 1 37 ± 1* 33 ± 1* 31 ± 1 36 ± 1* 
Carotid artery lumen diameter  
    (µm) 
412 ± 3 437 ± 7* 403 ± 4  416 ± 4 434 ± 4* 
Carotid artery constriction  
    (% tone from maximum  
    diameter) 
20 ± 1 20 ± 1 25 ± 1* 20 ± 1 19 ± 1 
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demonstrating reduced vascular SIRT1 expression and/or activity with age in 
rodents (12, 35) and humans (12, 20). In the present study, we show that SIRT1 
activation with SRT1720 can increase SIRT1 protein expression and activity in 
the aorta of aged mice to levels of young control animals.  
 
SIRT1 and Age-related Vascular Endothelial Dysfunction 
  The present findings are consistent with previous studies from our lab 
(25, 26, 35) and others (9, 21, 41) demonstrating reduced vascular endothelial 
function with advancing age, as indicated by impaired EDD. A previous report 
from our lab showed that inhibition of SIRT1 in femoral arteries removed age-
related differences in vascular function (12). Most importantly, the present results 
extend the previous findings and demonstrate that activation of SIRT1 restores 
EDD in old mice to levels similar to young animals.  
 SIRT1 has previously been reported to increase NO production via 
deacetylation of eNOS leading to increases in activity (12, 28). The present study 
found NO-mediated dilation tended to be reduced with age and decreased NO 
component of EDD with aging is consistent with previous findings in our lab (35, 
36). The current results shows that SIRT1 activation with SRT1720 did not 
restore NO-mediated dilation. The discrepancy in the effects of SIRT1-mediated 
NO production and vasodilation reported here with SRT1720 and those found by 
others might be due to the allosteric activation of SIRT1 with SRT1720, which is 
strongly dependent on substrate structure (7). Therefore, SRT1720 may not 
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increase SIRT1-mediated deacetylation of eNOS and subsequent NO 
generation. 
 Reductions in EDD with aging have been associated with loss of both NO- 
and COX-mediated dilation (37, 47). Our results show SIRT1 activation with 
SRT1720 in old mice improves EDD by enhancing the production of COX-2 
vasodilators. It has previously been shown that endothelial COX-2 production of 
vasodilators can preserve EDD despite loss of NO-mediated dilation (1, 16, 40), 
however to our knowledge this is the first evidence of SIRT1 enhancement of 
COX-2 vasodilation. 
 
Arterial Expression of Vasodilatory Enzymes  
 In the current study, we found an age-related reduction in aortic COX-2, 
which was restored with SRT1720 treatment, whereas there was no change in 
COX-1 or eNOS protein with age or treatment. To our knowledge, the current 
study is the first to demonstrate reduced vascular COX-2 expression with aging. 
Vascular expression of COX-1 has previously been found to increase (19, 29), 
decrease (6, 39), or not change (3) with age, however COX-2 expression has 
only been reported to increase (19, 29, 33) or not change (3, 10) with aging in the 
vasculature. Similar inconsistencies in age-related changes in vascular eNOS 
protein have been found (4, 6, 11, 38).  
 Importantly, the current results presented here demonstrating SIRT1-
mediated upregulation of COX-2 are consistent with a recent study showing 
SRT1720-mediated SIRT1 activation provides protection from apoptosis in 
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response to kidney injury by induction of renal COX-2 expression (18). Further, 
this previous study also suggested SIRT1 exerts transcriptional control of COX-2 
expression by demonstrating SIRT1 association with the COX2 gene promoter, 
and reduced COX-2 expression in heterozygous SIRT1 (Sirt1 +/-) mice (18). 
Collectively, these results suggest induction of COX-2 is an important 
mechanism mediating the protective effects of SIRT1 activation via SRT1720. 
 
Arterial Stiffness 
 Large elastic artery stiffness, as indicated by aortic PWV, was increased in 
both groups of old mice compared with young animals, which is consistent with 
previous reports from our lab (15, 36) and others (34). In the current study, PWV 
was selectively reduced post-treatment in old mice treated with SRT1720 to the 
level of young control animals, whereas no effect of SRT1720 was found in 
young mice. Notably, these results are the first to demonstrate SIRT1 activation 
reduces arterial stiffness in old mice. Additionally, the paired design of the 
present study extends previous observations from our lab showing cross-
sectional differences in aortic PWV with age and interventions in mice (15, 36). 
The reduction in PWV with four weeks of SRT1720 treatment in old mice further 
emphasizes the therapeutic potential of SIRT1 as a target for the treatment of 
arterial aging in humans.  
 The age-related increase in aortic PWV was associated with increased 
collagen I expression in the aorta of old mice, and SRT1720 treatment in old 
mice normalized the expression of collagen I to the level of young control mice. 
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We have previously reported age-related elevations in arterial expression of 
collagen I (14, 15), and SIRT1 activation with SRT1720 has been shown to 
reduce collagen I expression with kidney injury (18). SIRT1 has been reported to 
reduce calcification, a marker of arterial stiffness, in vascular smooth muscle 
cells in vitro with resveratrol (43), but to our knowledge this study is the first to 
report changes in arterial structural proteins with direct SIRT1 activation in vivo. 
 
Conclusions 
 The results reported in this study show for the first time that specific SIRT1 
activation with SRT1720 in old mice normalizes aortic SIRT1 expression and 
activity and ameliorates age-related vascular dysfunction and large elastic artery 
stiffness. Furthermore, our results indicate SIRT1 activation with SRT1720 
improves EDD via COX-2 vasodilators and restoration of aortic COX-2 protein 
expression. Previous reports of SIRT1-mediated beneficial effects on the 
vasculature have utilized genetic manipulation (28, 48) or non-specific activators 
(5) such as resveratrol. These results reinforce the potential of specific SIRT1 
activation as a therapeutic target for arterial aging and reducing the risk of age-
associated CVD in humans.  
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Abstract 
 Vascular endothelial dysfunction develops with advancing age, and this is 
characterized by reductions in endothelium-dependent dilation (EDD). 
Endothelial dysfunction is associated with elevations in oxidative stress and 
inflammation. Amelioration of these two key pathophysiological changes can 
improve age-related reductions in EDD. Vascular expression of the enzyme 
SIRT1 is reduced with age, and SIRT1 activation is associated with improved 
health span. We hypothesized that SIRT1 activation in old mice would reduce 
arterial superoxide production and inflammation. Young (4-9 months) and old 
(29-32 months) male B6D2F1 mice were treated with the SIRT1 activator 
SRT1720 (100 mg/kg BW) and old mice were treated with vehicle for four weeks. 
Young control mice (4-9 months) were also studied. Aortic superoxide production 
was increased 46% in old mice treated with vehicle compared to young control 
mice (p < 0.05), and this was reversed with in old mice treated with SRT1720. 
TEMPOL, a superoxide dismutase (SOD) mimetic, restored EDD in old vehicle-
treated mice (83 ± 3% vs 97 ± 1%, p < 0.01), whereas there was no effect of 
TEMPOL on EDD in young animals or old mice treated with SRT1720. SRT1720 
treatment increased arterial expression of managanese SOD 67% (p < 0.05) in 
old mice and 29% (p < 0.05) in young animals. Aortic expression of catalase was 
increased 190% (p < 0.05) in old and 134% (p < 0.05) in young mice treated with 
SRT1720 compared with young control animals. Aortic NF-!B activation was 
increased 12-fold with age (p < 0.05), but SRT1720 treatment in old mice 
reduced this to levels similar to young animals. Expression of the inflammatory 
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cytokines tumor necrosis factor (TNF)-" and interferon-# (IFN-#) were increased 
in the aorta of old mice treated with vehicle compared with young control mice (p 
< 0.05), and SIRT1 activation with SRT1720 in old mice reduced aortic 
expression of TNF-" and tended to reduce levels of IFN-#. Further, the effects of 
SRT1720 were confirmed to act through SIRT1 in HUVEC, as incubation with 
SRT1720 decreased the ratio of NF-!B acetyl-p65/total p65, and this was 
abolished with SIRT1 protein knock-down. Thus, SIRT1 activation with SRT1720 
in old mice ameliorates arterial oxidative stress and partially normalizes 
elevations in inflammation associated with age-related vascular dysfunction. 
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Introduction 
 Vascular endothelial dysfunction, as characterized by impaired 
endothelium-dependent dilation (EDD) develops with advancing age, and is 
predictive of future cardiovascular events (CVD) (1, 17, 23). Endothelial 
dysfunction involves “endothelial activation,” which represents a shift from a 
vasodilatory, antioxidant, and anti-inflammatory phenotype towards a 
constrictive, pro-inflammatory phenotype (6, 7). Therefore, two 
pathophysiological processes associated with vascular aging in both human and 
rodent models are increases in oxidative stress and inflammation (18).  
 Superoxide is one of the most significant sources of reactive oxygen 
species (ROS) in the vasculature (13). Animal models show age-related 
increases in the production of vascular superoxide (26, 27). Further, superoxide-
mediated suppression of EDD has been found with advancing age and TEMPOL, 
a superoxide dismutase (SOD) mimetic, improves EDD of older mice in isolated 
carotid arteries (11, 19, 26). Expression of antioxidant enzymes may also be 
changed with age in rodents, although this is not as clear. Extracellular SOD 
(ecSOD) expression has been found to both increase (11) and not change (27) 
with age. Manganese SOD (MnSOD) expression has been found to decrease 
(27) or not change (11, 26). Expression of copper-zinc SOD (CuZnSOD) is 
reported to not change with age (11, 27) in rodents. Therefore, elevations in ROS 
associated with aging may be due to both increases in production of ROS and 
possible decreases in antioxidant defense. 
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 Arterial aging is known to include a change in the expression pattern of 
pro-inflammatory cytokines (5, 6, 26, 27). A possible mediator in the role of 
inflammation with advancing age is the redox-sensitive transcription factor 
nuclear factor-!B (NF-!B) (6). NF-!B activation is greatly increased by 
intracellular ROS (3), and NF-!B activity can be regulated by post-translational 
modifications, such as phosphorylation and acetylation of the subunit p65 (6). 
Evidence of elevations in NF-!B signaling have been found in endothelial cells 
(EC) obtained from older humans (8, 9) and in the aorta of aged mice (20). 
Further, inhibition of NF-!B signaling improves EDD in older adults and mice, 
and this is associated with reductions in vascular oxidative stress and 
inflammation (20, 25). These studies clearly show that in addition to elevations in 
oxidative stress, age-related increases in inflammation and NF-!B activation can 
mediate the development of vascular endothelial dysfunction with age. 
 SIRT1 is a nicotinamide adenine dinucleotide-dependent deacetylase and 
a member of the sirtuin family of enzymes (14). SIRT1 activity is associated with 
improved longevity and health span (14). SIRT1 protein is reduced in EC and 
vascular tissue from older adults and rodents (10, 16), and has also been 
associated with age-related vascular dysfunction (10). SIRT1 activation is 
associated with upregulation of antioxidant enzyme expression (24, 29), and is 
protective against oxidative stress (4, 15). Activation of SIRT1 also reduces 
inflammation, as it has been shown to deacetylate NF-!B p65 (2) and reduce NF-
!B signaling and inflammatory cytokine expression in EC (4). 
! '$!
 In the present study, we hypothesized that four weeks of treatment with 
the specific SIRT1 activator SRT1720 would reduce arterial superoxide 
production in old mice and this would be associated with amelioration of 
superoxide-mediated suppression of EDD and reductions in aortic inflammation. 
Additionally, we sought to gain insight into whether reductions in vascular 
oxidative stress and inflammation were associated with changes in arterial 
antioxidant enzyme expression and levels of inflammatory cytokines. 
 
Methods  
Animals 
 Young (4-9 months) and old (29-32 months) male B6D2F1 mice were 
obtained from the National Institute on Aging rodent colony, and were fed normal 
rodent chow ad libitum. All mice were housed in an animal care facility at the 
University of Colorado at Boulder on a 12:12 light:dark cycle. Old and young 
mice were treated with 100 mg/kg body weight SRT1720 (Sirtris, a 
GlaxoSmithKline Co.; Cambridge, MA) or old mice were treated with vehicle 
(40%PEG-400/0.5% Tween-80/ 59.5% deionized water) for four weeks via oral 
gavage (21). Young cage control mice were also monitored for four weeks. Body 
weight was monitored weekly and at sacrifice. All animal procedures conformed 
to the Guide to the Care and Use of Laboratory Animals (NIH publication n. 85–
23, revised 1996) and were approved by the UCB Animal Care and Use 
Committee. 
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Cell Culture 
 
 Primary human umbilical vein EC (HUVEC) cultures were obtained from 
Lonza and grown in an endothelial cell-specific growth media system (Lonza). 
Experiments were performed on passage 3-4 cells. Lipofectamine 2000 
(Invitrogen) and SIRT1 siRNA (Invitrogen, #VHS50608) were used to reduce 
SIRT1 protein expression according to manufacturer’s instructions. SRT1720 (2 
µM) or 1% DMSO vehicle control were applied at 90% confluency for 1 hour 
before cells were harvested and frozen until further analysis. Each treatment 
represents the mean of triplicate wells. 
 
Arterial superoxide production 
 Production of superoxide was measured by EPR spectrometry using the 
spin probe 1-hydroxy-3-methoxycarbonly-2,2,5,5-te- tramethylpyrrolidine (CMH; 
Alexis Biochemicals, San Diego, CA, USA) as previously described (12, 26, 27). 
Two-millimeter aortic rings were incubated for 60 min at 37 °C in 200 µL of 
Krebs-HEPES buffer containing 0.55 mM CMH and analyzed immediately on an 
MS300 X-band EPR spectrometer (Magnettech, Berlin, Germany). 
 
Carotid Artery Vasodilatory Responses 
 
 Endothelium-dependent was determined ex vivo in isolated carotid 
arteries (11, 19, 26, 27). Carotid arteries were excised and cannulated onto glass 
micropipettes in myograph chambers (DMT Inc.). Arteries were pressurized to 50 
mmHg at 37oC and allowed to equilibrate. After preconstriction with 
phenylephrine (2 µmol/L), increases in luminal diameter in response to ACh 
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(1x10-9 – 1x10-4 M) with and without co-administration TEMPOL (1 mM, 60 min 
incubation) were determined. All dose response data are presented on a percent 
basis. 
 
Arterial protein expression and enzyme activities 
 Western blot analyses were performed on whole-cell human umbilical vein 
endothelial cells (HUVEC) lysates and cleaned mouse aortas to provide sufficient 
tissue for analysis as described previously (11, 19, 26). Fifteen micrograms of 
protein was loaded on 4–12% polyacrylamide gels, separated by electrophoresis, 
and transferred onto nitrocellulose membranes for Western blot analysis. 
Antibodies for Western blot analysis included SIRT-1 (1:1000; Abcam Inc.), 
MnSOD (1:2000, Stressgen), CuZnSOD (1:2000; Stressgen), extracellular SOD 
(ecSOD) (1:500; Sigma), catalase (1:2500; Abcam), Lysine310-acetyl NF-!B p65 
(1:500; Cell Signaling), and NF-!B p65 (1:1000; Cell Signaling). To account for 
differences in protein loading, expression is presented normalized to GAPDH 
(1:1000; 37 kDa; Cell Signaling) expression. These data also are expressed as a 
ratio of the mean of the young control group within a given set of lysates. Total 
SOD activity in aortic lysates (1 µg protein) was determined using the SOD 
Activity Assay kit (Cayman Chemical) according to the manufacturer’s 
instructions. Concentrations of the pro-inflammatory cytokines tumor necrosis 
factor (TNF)-" and interferon-# (IFN-#) were determined in aortic whole cell 
lysates by multiplex ELISA (Searchlight Mouse Inflammatory Cytokine Kit; 
Aushon Biosystems) as previously described (26). 
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Statistics 
 Results are presented as mean ± SEM. Statistical analysis was performed 
with SPSS 17.0 software (IBM, Somers, NY, USA).  For protein expression, 
enzyme activities, superoxide production, and ex vivo carotid artery maximal 
comparisons between groups were made using ANOVA. A paired t-test was 
used to analyze max dilation with or without incubation with TEMPOL. 
Significance was determined using P < 0.05. 
 
 
Results 
SIRT1 is required for the effects of SRT1720  
 To confirm the dependence of SIRT1 protein expression on the beneficial 
effects of SRT1720, HUVEC were incubated with SRT1720 in presence or 
absence of siRNA specific for SIRT1. SRT1720 treatment increased SIRT1 
protein expression 61% (p < 0.001), whereas SIRT1 siRNA effectively reduced 
SIRT1 expression in HUVEC compared with DMSO control treated cells (p < 
0.001) (Figure 1A). Further, SRT1720 treatment in HUVEC reduced ratio of NF-
!B acetyl-p65/total p65 22% (p < 0.05) (Figure 1B), and this was abolished in 
HUVEC pre-treated with SIRT1 siRNA (Figure 1B). These data confirm that 
SIRT1 is required for the beneficial changes observed with SRT1720 in vascular 
tissue and cells.  
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Figure 1 
 
Figure 1. SIRT1 expression is required for SRT1720-mediated effects. Protein 
expression of (A) SIRT1 and (B) ratio of NF-!B subunit acetyl-p65 to total p65 in 
human umbilical vein endothelial cells (HUVEC) treated with vehicle (Control), 
SRT1720, SIRT1-specific siRNA + SRT1720 (siRNA+SRT1720), scrambled 
siRNA (Scram siRNA), and scrambled siRNA + SRT1720 (Scram 
siRNA+SRT1720). Data are expressed relative to GAPDH and normalized to 
Control mean value. Representative Western blot images below. Values are 
mean ± SEM. *, p < 0.05 vs Control; †, p < 0.05 vs SRT1720. 
 
 
SIRT1 activation with SRT1720 reduces aortic superoxide production in old 
mice 
 Aortic superoxide production was 46% greater in the old mice treated with 
vehicle compared to young control mice (p < 0.05) (Figure 2). In contrast, 
SRT1720 treatment significantly reduced superoxide production in the old mice 
(p < 0.05) to levels similar to both young control and young SRT1720-treated 
animals (Figure 2). These results indicate that SRT1720 treatment reduces the 
age-associated increase in arterial superoxide production. 
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Figure 2 
 
Figure 2. Aortic superoxide production. Mean electron paramagnetic resonance 
signal of aortic rings (2 mm) from young control (YC), young SRT1720-treated 
(YS), old vehicle-treated (OV) and old SRT1720-treated (OS) mice. Values are 
mean ± SEM. *, p < 0.05 vs YC; †, p < 0.05 vs OV. 
 
SIRT1 activation with SRT1720 reduces superoxide-mediated suppression 
of dilation in old mice  
 Incubation with TEMPOL, a SOD mimetic, restored EDD in old vehicle-
treated mice (83 ± 3% vs 97 ± 1%, p < 0.01) (Figure 3). In contrast, TEMPOL did 
not affect EDD in old SRT1720-treated mice or young animals (Figure 3). This 
indicates that superoxide suppresses EDD in old vehicle control mice, and 
SRT1720 treatment reduced vascular superoxide bioactivity.  
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Figure 3 
 
 
Figure 3. Superoxide-dependent modulation of endothelium-dependent dilation. 
Maximal dilation of carotid arteries to acetylcholine (ACh) and to ACh + 
TEMPOL, a superoxide dismutase mimetic, in young control (YC), young 
SRT1720-treated (YS), old vehicle-treated (OV) and old SRT1720-treated (OS) 
mice. Values are mean ± SEM. *, p < 0.05 vs OV ACh. 
 
SIRT1 activation with SRT1720 increases aortic antioxidant enzyme 
expression in young and old mice 
 Aortic protein expression of MnSOD was unchanged in old vehicle-treated 
mice compared with young control mice (Figure 4A). However, SRT1720 
increased MnSOD protein expression 67% (p < 0.05) in old mice and 29% (p < 
0.05) in young animals (Figure 4A). Expression of CuZnSOD was unchanged 
with age, whereas SRT1720 increased expression 67% in old and 104% in 
young mice compared with young control animals (both p < 0.01) (Figure 4B). 
ecSOD protein expression was elevated 36% (p < 0.05) in old mice treated with 
vehicle compared to young control mice, and this increase was unaffected by 
SRT1720 treatment in old mice (Figure 4C). Aortic expression of catalase was 
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unchanged with age in old vehicle-treated mice, whereas SRT1720 treatment 
increased expression 190% (p < 0.05) in old and 134% (p < 0.05) in young mice 
compared with young control animals (Figure 4D). These data suggest SIRT1 
selectively increases antioxidant enzyme expression in aorta of young and old 
mice. 
 
Figure 4 
 
Figure 4. Arterial antioxidant enzymes. Protein expression of manganese 
superoxide dismutase (MnSOD), (B) copper zinc superoxide dismutase 
(CuZnSOD), (C) extracellular superoxide dismutase (ecSOD) and (D) catalase 
from young control (YC), young SRT1720-treated (YS), old vehicle-treated (OV) 
and old SRT1720-treated (OS) mice. Representative Western blot images below. 
Values are mean ± SEM. *, p < 0.05 vs YC; †, p < 0.05 vs OV. 
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SIRT1 activation with SRT1720 reduces aortic inflammation in old mice 
 Aortic NF-!B activation, assessed by the NF-!B acetyl-p65/total p65 ratio, 
was increased 12-fold in old vehicle-treated mice compared with young control 
mice (p < 0.05), but was reduced in old SRT1720-treated mice to levels similar to 
young animals (Figure 5A). Expression of the inflammatory cytokine TNF-" was 
increased in aorta of old vehicle-treated mice compared with young control mice 
(p < 0.01) (Figure 5B). SIRT1 activation reduced expression (p < 0.05) in old 
mice, whereas there was no effect in young mice (Figure 5B). Protein expression 
of the inflammatory cytokine IFN-# was increased in aorta of old mice treated 
with vehicle compared with young control mice (p < 0.05) (Figure 5C). SRT1720 
treatment tended to reduce aortic expression in old mice (p = 0.1), but had no 
effect in young animals. These data indicate that four weeks of SIRT1 activation 
with SRT1720 reduces NF-!B activation, which may contribute to decreased 
inflammatory NF-!B signaling, and this is associated with partially normalized 
arterial inflammation in old mice. 
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Figure 5 
 
Figure 5. Arterial inflammation. Aortic protein expression of (A) ratio of nuclear 
factor-!B (NF-!B) subunit acetyl-p65 to total p65, (B) tumor necrosis factor-" 
(TNF- ") and (C) interferon-# (IFN-#) in young control (YC), young SRT1720-
treated (YS), old vehicle-treated (OV) and old SRT1720-treated (OS) mice. 
Representative Western blot images below. Values are mean ± SEM. *, p < 0.05 
vs YC; †, p < 0.05 vs OV; §, p=0.1 vs. OV. 
 
 
Discussion 
 
 The novel findings of the present studies are that four weeks treatment 
with the SIRT1 activator SRT1720 reduced age-related increases in arterial 
superoxide production and aortic suppression of oxidative stress, and this was 
accompanied by increases in arterial antioxidant enzyme expression. Our results 
also show that SIRT1 activation decreased NF-!B activation and partially 
normalized inflammatory cytokine expression in the aorta of old mice. 
Additionally, we demonstrated that the effects of SRT1720 require SIRT1 
signaling in vitro in HUVEC. 
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Validation effects of SRT1720 require SIRT1  
 The effects of SRT1720 were confirmed to act through SIRT1 in HUVEC. 
Incubation with SRT1720 reduced the ratio of NF-!B acetyl-p65/total p65 in 
HUVEC compared to control treated cells. This decrease in the ratio of NF-!B 
acetyl-p65/total p65 was abolished in HUVEC pre-treated with SIRT1-specific 
siRNA. These results validate the effects of SRT1720 are mediated through 
SIRT1. 
 
 
Arterial oxidative stress 
 The present finding of increased superoxide production in aortic rings from 
old mice is consistent with previous findings by our lab (12, 26, 27). Reductions 
in vascular superoxide production have been shown with resveratrol in EC (28) 
and with SRT1720 in vivo (22). However, this is the first evidence of reduced 
aortic superoxide production with specific SIRT1 activation with SRT1720. 
 Since we found SIRT1 activation with SRT1720 reduced aortic superoxide 
production, we then investigated whether this decrease in vascular ROS affected 
vascular function. As was previously reported in the first paper of this 
dissertation, old mice treated with vehicle demonstrated reduced dilation to EDD 
compared with that of young control mice. The results of the current study show 
that incubation with the SOD mimetic, TEMPOL, restored dilation to ACh in old 
vehicle-treated mice, but had no effect in old mice treated with SRT1720. 
Importantly, the present results extend the previous findings showing SIRT1 
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activation increases EDD and demonstrate that activation of SIRT1 with 
SRT1720 abolishes superoxide-mediated suppression in old mice.  
 SIRT1 activation has been reported to induce expression of antioxidant 
enzymes MnSOD (24, 29) and catalase (24), and our results showing SIRT1 
activation with SRT1720 upregulated expression of MnSOD and catalase in the 
aorta of young and old mice are consistent with these previous observations. 
Previous studies from our lab have found differential changes in arterial 
antioxidant enzyme expression with age (11, 26, 27). In the current study we 
additionally found upregulation of ecSOD in old mice treated with vehicle 
compared with young control animals, and this age-associated increase was not 
affected by SRT1720 treatment. These observations indicate SRT1720-mediated 
SIRT1 activation increases antioxidant enzyme expression and this is associated 
with reduced superoxide production in aorta of old mice. 
 
Arterial Inflammation 
 
 In the current study, we found an increase in aortic NF-!B activation with 
age, and this is consistent with previous results from our lab (20). SIRT1 has 
previously been shown to modulate NF-!B activation by direct deacetylation of 
the p65 subunit resulting in inhibition of NF-!B transcriptional activity (30). In EC, 
SIRT1 inhibition increases acetylation of NF-!B p65 and enhances activation NF-
!B activation (2). However to our knowledge this is the first evidence of that 
SIRT1 activation ameliorates the increase in NF-!B activation in aorta of old 
mice.  
! (&!
 The increase in arterial NF-!B activation with aging was associated with 
increases in aortic inflammatory cytokines, which is consistent with previous 
findings from our lab (20). The current results show SIRT1 activation with 
SRT1720 in old mice decreased arterial expression of TNF-" and tended to 
reduce levels of IFN-#. Decreases in inflammation have been reported with 
SIRT1 activation (4), however to our knowledge this is the first study to report 
partial normalization of age-related changes in arterial inflammatory cytokines 
with direct SIRT1 activation with SRT1720. Collectively, these results suggest 
reductions in arterial inflammation contribute to the protective effects of SIRT1 
with SRT1720 in old mice. 
  
 
Conclusions 
 The results of the current study show specific SIRT1 activation with 
SRT1720 ameliorates age-related increases in arterial superoxide production 
and superoxide-mediated suppression of EDD, and increases antioxidant 
enzyme expression. Further, we show that SIRT1 activation reduces NF-!B 
signaling and partially normalizes inflammation in old mice. Elevations in 
inflammation and oxidative stress are two key mediators of vascular dysfunction 
with age. Therefore, specific SIRT1 activation may be a therapeutic target to 
reduce age-related increases in CVD risk in humans. 
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CHAPTER VI 
 
 
 
Conclusions 
 
 
 I tested two hypotheses to determine the effects of specific SIRT1 
activation with SRT1720 on age-related vascular dysfunction. First, I found old 
mice demonstrate reduced arterial SIRT1 protein and activity compared with 
young control animals, and administration of SRT1720 for four weeks in old 
animals restored aortic SIRT1 expression and activity. SRT1720-mediated SIRT1 
activation ameliorated the age-related impairment in endothelium-dependent 
dilation (EDD) by increasing the production of COX-2 vasodilators, and this was 
associated with restoration of arterial COX-2 expression. SIRT1 activation also 
reduced arterial pulse wave velocity in old mice, and reduced aortic collagen I 
expression. Second, I found SIRT1 activation with SRT1720 reduced aortic 
superoxide production and abolished age-related superoxide-mediated 
suppression of EDD. Old vehicle-treated mice demonstrated increased aortic NF-
!B activation compared with young control animals, and this was reversed in old 
mice with SIRT1 activation. The reduction in arterial NF-!B activation was 
associated with partial normalization of inflammatory cytokine expression in old 
SRT1720-treated animals. 
 In summary, these studies are the first to show specific SIRT1 activation 
restores aortic SIRT1 activity and expression in old mice, and reduces age-
related vascular dysfunction. Vascular endothelial dysfunction and arterial 
stiffness are independent risk factors for the development of future 
! )"!
cardiovascular disease (CVD), and therapies designed to reduce arterial aging 
are important therapeutic targets to reduce CVD events in older adults. SIRT1 
has recently emerged as a key clinical target for the treatment of many age-
related diseases. These studies emphasize the potential of pharmacological 
modulation of SIRT1 activity as a therapy to improve vascular function and 
reduce CVD mortality and morbidity. !
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